streptomycin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 2481 | 57-92-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 55 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 34.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.34 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.78 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.65 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 1946 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug resistance | 180.18 | 34.68 | 46 | 889 | 17322 | 46667805 |
| Drug reaction with eosinophilia and systemic symptoms | 65.75 | 34.68 | 24 | 911 | 29524 | 46655603 |
| Paradoxical drug reaction | 60.07 | 34.68 | 13 | 922 | 2363 | 46682764 |
| Tuberculosis | 45.40 | 34.68 | 14 | 921 | 10251 | 46674876 |
| Pulmonary tuberculosis | 36.74 | 34.68 | 10 | 925 | 4721 | 46680406 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 204.64 | 36.88 | 41 | 1136 | 2621 | 29948680 |
| Drug resistance | 159.15 | 36.88 | 50 | 1127 | 20083 | 29931218 |
| Tuberculosis | 102.60 | 36.88 | 29 | 1148 | 8048 | 29943253 |
| Tuberculoma of central nervous system | 99.80 | 36.88 | 16 | 1161 | 279 | 29951022 |
| Immune reconstitution inflammatory syndrome | 99.18 | 36.88 | 29 | 1148 | 9072 | 29942229 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 54.01 | 36.88 | 10 | 1167 | 415 | 29950886 |
| Pulmonary tuberculosis | 46.41 | 36.88 | 14 | 1163 | 4843 | 29946458 |
| Optic neuropathy | 40.50 | 36.88 | 10 | 1167 | 1639 | 29949662 |
| Meningitis tuberculous | 39.15 | 36.88 | 8 | 1169 | 557 | 29950744 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07AA04 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | A07AA54 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | J01GA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Streptomycins |
| ATC | J04AM01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| FDA CS | M0000946 | Aminoglycosides |
| FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
| FDA EPC | N0000175483 | Antimycobacterial |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:36043 | antimicrobial drugs |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
| CHEBI has role | CHEBI:86328 | antifungal agrichemical |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tularemia | indication | 19265001 | |
| Acute tuberculosis | indication | 25629007 | |
| Granuloma inguinale | indication | 28867007 | DOID:9113 |
| Plague | indication | 58750007 | DOID:3482 |
| Klebsiella cystitis | indication | 60867007 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Brucellosis | indication | 75702008 | DOID:11077 |
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Chancroid | indication | 266143009 | DOID:13778 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Bacterial urinary infection | indication | 312124009 | |
| Aerobic Gram-Negative Bacteremia | indication | ||
| Synergy for Streptococcal Endocarditis | indication | ||
| Haemophilus Endocarditis | indication | ||
| Synergy for Enterococcal Endocarditis | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| Synergy for Enterococcal Infections | indication | ||
| H. Influenzae Meningitis | indication | ||
| Pulmonary Mycobacterium avium complex infection | off-label use | 186342000 | |
| Hypocalcemia | contraindication | 5291005 | |
| Parkinsonism | contraindication | 32798002 | |
| Dehydration | contraindication | 34095006 | |
| Tinnitus | contraindication | 60862001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Pregnancy, function | contraindication | 289908002 | |
| Vertigo | contraindication | 399153001 | |
| Inner Ear Disturbance | contraindication | ||
| Disorder of the 8th Cranial Nerve | contraindication | ||
| Infant Botulism | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.43 | acidic |
| pKa2 | 12.62 | acidic |
| pKa3 | 13.36 | acidic |
| pKa4 | 13.79 | acidic |
| pKa5 | 11.91 | Basic |
| pKa6 | 11.21 | Basic |
| pKa7 | 6.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 30S ribosomal protein S12 | Ribosomal protein | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019933 | VUID |
| N0000148018 | NUI |
| D01350 | KEGG_DRUG |
| 3810-74-0 | SECONDARY_CAS_RN |
| 4017475 | VANDF |
| 4019933 | VANDF |
| C0038425 | UMLSCUI |
| CHEBI:58007 | CHEBI |
| SRY | PDB_CHEM_ID |
| CHEMBL372795 | ChEMBL_ID |
| CHEMBL453087 | ChEMBL_ID |
| CHEMBL3184791 | ChEMBL_ID |
| D013307 | MESH_DESCRIPTOR_UI |
| 10923 | IUPHAR_LIGAND_ID |
| 3685 | INN_ID |
| DB01082 | DRUGBANK_ID |
| Y45QSO73OB | UNII |
| 19649 | PUBCHEM_CID |
| 10109 | RXNORM |
| 1794 | MMSL |
| 5514 | MMSL |
| d00159 | MMSL |
| 002770 | NDDF |
| 004895 | NDDF |
| 387223008 | SNOMEDCT_US |
| 40877002 | SNOMEDCT_US |
| 73246001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |